15 results
8-K
EX-99.2
GLYC
GlycoMimetics Inc
6 May 24
Results of Operations and Financial Condition
4:01pm
opioid use Dampier et al, Blood 2023 Early Treatment Resulted in Clinical Benefit For patients treated within first quartile of treatment (<
8-K
EX-99.1
GLYC
GlycoMimetics Inc
1 Mar 24
Regulation FD Disclosure
9:16am
= time to discharge; TTDIVO = time to discontinuation of IV opioids; CIVO = cumulative IV opioid use Dampier et al, Blood 2023 Early Treatment Resulted
8-K
EX-99.1
GLYC
GlycoMimetics Inc
4 Oct 22
Regulation FD Disclosure
5:03pm
Benefit 17 TTRD = time to readiness for discharge; TTD = time to discharge; TTDIVO = time to discontinuation of IV opioids; CIVO = cumulative IV opioid
8-K
EX-99.1
GLYC
GlycoMimetics Inc
5 Aug 19
Glycomimetics Reports Top-line Results from Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel In Sickle Cell Disease
4:30pm
and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids.
“We are both
8-K
EX-99.1
h3rbqixl237q
25 Jul 18
Regulation FD Disclosure
8:30am
10-K
bv5awrtaoto72m vnu
31 Mar 14
Annual report
12:00am
424B4
7o8zf1bt6s
10 Jan 14
Prospectus supplement with pricing info
12:00am
S-1
ulzmt52
4 Oct 13
IPO registration
12:00am
- Prev
- 1
- Next